Who Gains Most? A 10-Year Experience With 611 Thoracoscopic Talc Pleurodeses

Steger, Volker; Mika, Ute; Toomes, H.; Walker, Tobias; Engel, Corinna; Kyriss, Thomas; Ziemer, Gerhard; Friedel, Godehard

doi:10.1016/j.athoracsur.2007.02.061

Cited by 55 publications

(35 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One of the standard therapeutic strategies to prevent recurrent MPE is chemical pleurodesis using talcum. However, despite therapeutic intervention, recurrence rate is high and prognosis remains poor [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110

Witthauer

Schlereth

Brischwein

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

In the present study, the efficacy of a new drug, i.e. the bispecific single-chain antibody MT110 targeting the epithelial antigen EpCAM and the T-cell antigen CD3 was tested ex vivo in malignant pleural effusions (MPEs). EpCAM ? epithelial cells were found in 78% of the MPEs (n = 18). Ex vivo treatment of seven MPEs resulted in a dose-dependent specific lysis of 37 ± 27% (±SD) EpCAM ? cells with 10 ng/ml (P = 0.03) and 57 ± 29.5% EpCAM ? cells with 1,000 ng/ml MT110 (P = 0.016) after 72 h. As a prerequisite for redirected lysis, stimulation of he autologous CD4 ? and CD8 ? cells in MPE by 1,000 ng/ml MT110 resulted in 21 ± 17% CD4 ? /CD25 ? and 29.4 ± 22% CD8 ? /CD25 ? cells (P = 0.016, respectively) after 72 h. This was confirmed by a 22-fold release of TNF-a and 230-fold release of IFN-c (1,000 ng/ml, 48 h, P = 0.03, respectively). Thus, relapsed breast cancer patients resistant to standard treatment might benefit from targeted therapy using MT110.Keywords Malignant pleural effusion Á Breast cancer Á Bispecific antibody Á EpCAM Á CD3 Á MT110 Á Ex vivo therapy

show abstract

Section: Introductionmentioning

confidence: 99%

Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110

Witthauer

Schlereth

Brischwein

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Chemical pleurodesis may be used in selected patients with acceptable performance status and life expectancy greater than 3 months to relieve symptoms, prevent fl uid recurrence, and improve the quality of life. 1,4 Talc is widely recognized as the sclerosant agent of choice in view of its clinical effi cacy, safety profi le, and low cost, whereas thoracoscopic talc pleurodesis has been suggested as the most effective pleurodesis technique. 2,3,5 In fact, during video-assisted thoracoscopy, pleural fl uid can be removed completely, loculations and adhesions can be divided when present, and talc can be insuffl ated equally in the pleural space under visual control.…”

Section: Discussionmentioning

confidence: 99%

“…1,6 However, in patients who do not have a "trapped" lung, the failure rate of talc pleurodesis, reported in the literature, is still about 10%. In our department, the successful rate, before introducing this new device, was around 80-90%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Suitable device for thoracoscopic talc poudrage in malignant pleural effusion

Billè

Borasio

Gisabella

et al. 2011

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Chemical pleurodesis is widely used in symptomatic patients with malignant pleural effusion to relieve symptoms, prevent fl uid recurrence, and improve quality of life. Talc has been repeatedly found to be the most effective sclerosant agent, and thoracoscopic talc poudrage has been found to be the most effective pleurodesis technique. A homogeneous talc distribution on the visceral and parietal pleura helps to achieve complete pleural symphysis. We have recently adopted a new suitable sterile device that delivers talc under low and constant pressure, facilitating uniform coating of the whole pleural surface and avoiding inappropriate deposition of talc clumps.

show abstract

“…This study, however, did exclude patients undergoing more than one attempt at pleurodesis and the specific aetiologies amongst the included non-malignant effusions is not clear [64]. GLAZER et al [65] reported a success rate of 75% with talc pleurodesis in 16 non-malignant effusions of varying aetiology.…”

Section: Pleurodesismentioning

confidence: 99%

The management of benign non-infective pleural effusions

et al. 2016

View full text Add to dashboard Cite

The evidence base concerning the management of benign pleural effusions has lagged behind that of malignant pleural effusions in which recent randomised trials are now informing current clinical practice and international guidelines.The causes of benign pleural effusions are broad, heterogenous and patients may benefit from individualised management targeted at both treating the underlying disease process and direct management of the fluid. Pleural effusions are very common in a number of non-malignant pathologies, such as decompensated heart failure, and following coronary artery bypass grafting. Pleural fluid analysis forms an important basis of the diagnostic evaluation, and more specific assays and imaging modalities are helpful in specific subpopulations.Options for management beyond treatment of the underlying disorder, whenever possible, include therapeutically aspirating the fluid, talc pleurodesis and insertion of an indwelling pleural catheter. Randomised trials will inform clinicians in the future as to the risks and benefits of these options providing a guide as to how best to manage patient symptoms in this challenging clinical setting. @ERSpublications Benign pleural effusion management is challenging and based on limited evidence. Treatment options are discussed http://ow.ly/10EOSN

show abstract

Who Gains Most? A 10-Year Experience With 611 Thoracoscopic Talc Pleurodeses

Cited by 55 publications

References 38 publications

Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110

Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110

Suitable device for thoracoscopic talc poudrage in malignant pleural effusion

The management of benign non-infective pleural effusions

Contact Info

Product

Resources

About